|Mirosław Szmidt1, Dorota Brzostek2|
1)II Klinika GruĽlicy i Chorób Płuc Instytutu GruĽlicy i Chorób Płuc w Warszawie, ul Okólna 181, 91-520 ŁódĽ
2)Glaxo Wellcome Polska, al. Jana Pawła II 34, 00-141 Warszawa
Salmeterol is a potent long acting bronchodilatator, with twelve hours duration of action. It is also the most ?2 receptor specific adrenergic drug. After very promising results in asthma treatment, the role of salmeterol in Chronic Obstructive Pulmonary Disease (COPD) had to be determined. Based on the results of clinical trials where functional respiratory paramters were measured (FEV1, Rt) it has been shown that salmeterol has an equally strong but longer lasting effect then ipratropium bromide. In the advanced stage of illnes, although the bronchodilatatory effect is less prononunced, salmeterol protects against effort induced bronchostriction and ameliorates physical excercise tolerance. The usual dose of salmeterol is 50 µg every 12 hours, in advanced COPD also 25 µg every 12 hours is efficient. In vitro tests have shown that salmeterol decreases the cellular damage caused by bacterial toxins. Regular long-term usage of salmeterol is not only safe but also decreases by 50% the amount of bacterial exacerbations in COPD.
Because of it's bronchodilatating and bronchoprotective properties salmeterol should be widely used, not only in asthma, but also in COPD.
pages: from 149 to 153
|estimated time of download (63 kB)|